A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine ®, a high-purity factor IX concentrate, in patients with severe haemophilia B

Haemophilia

Volumn 17, Issue 4, 2011, Pages 590-596

  Lissitchkov, T ^a   Matysiak, M ^b   Zavilska, K ^c   Laguna P ^b   Gercheva, L ^d   Antonov, A ^e   Cabrera, N ^f   Aznar, J A ^f   Woodward, M K ^g   Paez A ^g  

^a National Center of Hematology   (Bulgaria)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c J Strus Hospital   (Poland)

^d UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^e MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

^f HOSPITAL UNIVERSITARIO LA FE   (Spain)

^g Instituto Grifols S A Parets del Vallès   (Spain)

Author keywords

AlphaNine ; Efficacy; Factor IX; Haemophilia; Haemophilia B; Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ABDOMINAL DISCOMFORT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOGENICITY; MULTICENTER STUDY; PRIORITY JOURNAL; SIDE EFFECT; THROMBOGENICITY; THROMBOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; FACTOR IX; FOLLOW-UP STUDIES; HEMOPHILIA B; HEMOSTASIS; HUMANS; YOUNG ADULT;

EID: 79959499738     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02470.x     Document Type: Article

References (31)

1. Bolton-Maggs PH, Pasi KJ. Hemophilias A and B. Lancet 2003; 361: 1801-9.
2. Hemophilia B Mutation database. database of point. Last accessed: March 15, 2010.
3. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. N Engl J Med 1992; 326: 800-6.
4. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Hemost 1997; 78: 61-265.
5. Wasley LC, Rehemtulla A, Bristol JA et al. PACE/furin can process the vitamin K-dependent pro-factor IX precursor within the secretory pathway. J Biol Chem 1993; 268: 8458-65.
6. Roosendal G, Lafeber FP. Pathogenesis of hemophilic arthropathy. Haemophilia 2006; 12(Suppl. 3): 117-21.
7. de Tezanos Pinto M, Fernandez J, Perez Bianco PR. Update of 156 episodes of central nervous system in hemophiliacs. Hemostasis 1992; 22: 259-67.
8. Kim HC, Matts L, Eisele J, Czachur M, Saidi P. Monoclonal antibody-purified factor IX-comparative thrombogenicity to prothrombin complex concentrate. Semin Hematol 1991; 28(Suppl. 6): 15-9.
9. Lowe GD. Factor IX and thrombosis. Br J Hematol 2001; 115: 507-13.
10. Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res 1999; 95(Suppl. 1): S13-7.
11. Schulman S, Wallensten R, White B, Smith OP. Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in hemophilia patients undergoing surgery. Haemophilia 1999; 5: 96-100.
12. The European Agency for the Evaluation of Medicinal Products (EMEA). Note for Guidance on the clinical investigation of human plasma derived factor VIII and IX products (CPMP/BPWP/198/95 rev.1), London, October 19th, 2000.
13. Lee M, Morfini M, Schulman S, Ingerslev J and the factor VIII/factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Hemostasis Scientific and Standardization Committee communication. The Design and Analysis of Pharmacokinetic Studies of Coagulation factors. Posted on ISTH Website 21 March, 2001. Available at .
14. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with hemophilia. Clin Pharmacokinet 2001; 40: 815-32.
15. Morfini M, Laguna P, Leissinger C. Factor IX pharmacokinetics: differences between plasma-derived and recombinant products and the clinical and economic implications: a meeting report. Haemophilia 2008; 14: 873-5.
16. Carlsson M, Björkman S, Berntorp E. Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis. Haemophilia 1998; 4: 83-8.
17. Shapiro AD, Korth-Bradley J, Poon MC. Use of pharmacokinetics in the coagulation factor treatment of patients with hemophilia. Haemophilia 2005; 11: 571-82.
18. Björkman S, Folkesson A, Berntorp E. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting. Haemophilia 2007; 13: 2-8.
19. Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9(Suppl. 1): 94-9.
20. Aznar JA, Cabrera N, Matysiak M et al. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe hemophilia B. Haemophilia 2009; 15: 1243-8.
21. Berntorp E, Björkman S, Carlsson M, Lethagen S, Nilsson IM. Biochemical and in vivo properties of high purity factor IX concentrates. Thrombos Hemost 1993; 70: 768-73.
22. Ewenstein BM, Joist JH, Shapiro AD et al. Pharmacokinetic analysis of plasma-derived and recombinant FIX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion 2002; 42: 190-7.
23. Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9: 353-9.
24. Poon MC. Pharmacokinetics of factors IX, recombinant human activated factor VII and factor XIII. Haemophilia 2006; 12(Suppl. 4): 61-9.
25. Roth DA, Kessler CM, Pasi KJ et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
26. Lambert T, Recht M, Valentino LA et al. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe hemophilia B. Haemophilia 2007; 13: 233-43.
27. White GC, Shapiro AD, Kurczynski EM, Kim HC, Bergman GE, the Mononine Study group. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. Thromb Hemost 1995; 73: 779-84.
28. Jorquera JI. Safety procedures of coagulation factors. Haemophilia 2007; 13: 41-6.
29. Foster PR. Removal of TSE agents from blood products. Vox Sang 2004; 87: S7-10.
30. Burnouf T, Padilla A. Current strategies to prevent transmission of prions by human plasma derivatives. Transfus Clin Biol 2006; 13: 320-8.
31. Biescas H, Nieto S, Caballero S, Díez JM, Gajardo R, Jorquera JI. Efficacy of plasma derivatives purification processes to eliminate an experimental TSE-model agent. Haemophilia 2006; 12(Suppl. 2): 5.